• Join
  • Login
  • Contact

Search abstracts / presentations

Analysis tamoxifen, endoxifen, and 4-hydroxytamoxifen in dbs of breast cancer patients by lc-ms/ms

  • In: D25 What’s new in industry & science? Part 2 on Thursday, 6 September 2018, 09:10 -09:20
  • At: Glasgow (Scotland) (2018)
  • Type: Presentation
  • By: HARAHAP, Yahdiana (Universitas Indonesia, Indonesia)
  • Co-author(s): Yahdiana Harahap
    Baitha Palanggatan Maggadani: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Tesanika Ribka Joulin Sitorus: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Callista Andinie Mulyadi: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Denni Joko Purwanto: Dharmais Cancer Hospital, Dharmais Cancer Hospital, Jakarta, Indonesia
  • Abstract:


    The antiestrogen effect of tamoxifen is highly determined by its active metabolites, 4-Hydroxytamoxifen (endoxifen) and 4-Hydroxy-N-Desmethyltamoxifen (4-OHTAM). Monitoring concentration of analyte and metabolites in DBS helps to improve effectiveness of therapy by minimizing drug toxicity and ensuring appropriate dosage regiment with


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses